Abstract
Parallel trade is a legitimate method of pharmaceutical import and export
within the EU zone. Although previously recognized in North America as
illegal, cross-border reimportation is now permitted following legislation
allowing drugs to be imported into the US from Canada. However, counterfeit
drugs have been shown to be increasingly introduced into the global supply
chain, which threatens patient safety, ethical pharmaceutical sales, and
undermines the integrity of the distribution channels. Parallel trade is
regarded as a major contributor to counterfeiting and this is explored in the
report. Furthermore, the report provides a comprehensive account of the route
of market access for counterfeits and shows how companies and governments in
Europe and North America are tackling the problem strategically. It also
updates the reader on the latest parallel trade and anti-counterfeiting
initiatives adopted globally and whether current efforts to stem the practice
have been successful or not. The report discusses further action plans and
recommends which strategies are likely to best curtail the practice. This
report also evaluates the extent of parallel trade in Europe and
counterfeiting globally with an analysis of major counterfeit-producing
countries and the anti-counterfeiting efforts currently in place.
| 
View Cart
